

# “Blanket” switching of inhaler types

## Why is this a bad idea?



*References and other articles which may be of interest*

## References

1. Prescription Cost Analysis - England, 2018 [PAS] - NHS England Digital. Accessed November 6, 2024. <https://digital.nhs.uk/data-and-information/publications/statistical/prescription-cost-analysis/2018>
2. Murphy AC. Inhalers: to switch or not to switch? That is the question. *Thorax*. 2020;75(3):e1. doi:10.1136/thoraxjnl-2019-214220. <https://thorax.bmj.com/content/75/3/e1>
3. NHS Long Term Plan v1.2 August 2019 | Enhanced Reader. <https://www.longtermplan.nhs.uk/wp-content/uploads/2019/08/nhs-long-term-plan-version-1.2.pdf>
4. UK Parliament UK Progress on Reducing F-gas Emissions | Enhanced Reader. <https://publications.parliament.uk/pa/cm201719/cmselect/cmenvaud/469/469.pdf>
5. DEMOS Potential Limited: The economic cost of uncontrolled asthma | Enhanced Reader. <https://demos.co.uk/wp-content/uploads/2023/02/Potential-Limited-Updated-03.21.pdf>
6. Orlovic M, Tzelis D, Guerra I, et al. Environmental, healthcare and societal impacts of asthma: a UK model-based assessment. *ERJ Open Res*. 2024;10(4):00577-02023. doi:10.1183/23120541.00577-2023. <https://pubmed.ncbi.nlm.nih.gov/39040585/>
7. Usmani OS, Bosnic-Anticevich S, Dekhuijzen R, et al. Real-World Impact of Nonclinical Inhaler Regimen Switches on Asthma or COPD: A Systematic Review. *Journal of Allergy and Clinical Immunology: In Practice*. 2022;10(10):2624-2637. doi:10.1016/j.jaip.2022.05.039. <https://pubmed.ncbi.nlm.nih.gov/35750323/>
8. Primary Care Respiratory Society (PCRS). Guidance on making safe and clinically appropriate changes to inhalers. 2022. <https://www.pcrs-uk.org/resource/current/pcrs-guidance-making-safe-and-clinically-appropriate-changes-inhalers>
9. Primary Care Respiratory Society (PCRS). Tailoring Inhaler Choice. 2024. <https://www.pcrs-uk.org/resource/current/tailoring-inhaler-devices>
10. South East London Respiratory Prescribing Group. Position statement - Environmental Impact of Inhalers. November 2021. [https://www.selondonics.org/wp-content/uploads/dlm\\_uploads/2022/11/Environmental-Impact-of-Inhalers-Position-Statement-December-2021.pdf](https://www.selondonics.org/wp-content/uploads/dlm_uploads/2022/11/Environmental-Impact-of-Inhalers-Position-Statement-December-2021.pdf)
11. BTS/SIGN Guideline for the Management of Asthma.; 2019. Accessed November 6, 2024. <https://www.brit-thoracic.org.uk/quality-improvement/guidelines/asthma/>
12. Saunders KB. Misuse of Inhaled Bronchodilator Agents. *Br Med J*. 1965;1(5441):1037-1038. doi:10.1136/BMJ.1.5441.1037. <https://pubmed.ncbi.nlm.nih.gov/14262196/>
13. Chrystyn H, van der Palen J, Sharma R, et al. Device errors in asthma and COPD: systematic literature review and meta-analysis. *NPJ Prim Care Respir Med*. 2017;27(1):22. doi:10.1038/s41533-017-0016-z. <https://pubmed.ncbi.nlm.nih.gov/28373682/>

## References (continued)

14. Giraud V, Roche N. Misuse of corticosteroid metered-dose inhaler is associated with decreased asthma stability. *European Respiratory Journal*. 19(2):246-251. doi:10.1183/09031936.02.00218402. <https://publications.ersnet.org/content/erj/19/2/246>
15. Levy ML, Hardwell A, McKnight E, Holmes J. Asthma patients' inability to use a pressurised metered-dose inhaler (pMDI) correctly correlates with poor asthma control as defined by the Global Initiative for Asthma (GINA) strategy: a retrospective analysis. *Primary Care Respiratory Journal*. 2013;22(4):406-411. doi:10.4104/pcrj.2013.00084. <https://pubmed.ncbi.nlm.nih.gov/24042172/>
16. Plaza V, Giner J, Rodrigo GJ, Dolovich MB, Sanchis J. Errors in the Use of Inhalers by Health Care Professionals: A Systematic Review. *J Allergy Clin Immunol Pract*. 2018;6(3):987-995. doi:10.1016/J.JAIP.2017.12.032. <https://pubmed.ncbi.nlm.nih.gov/29355645/>
17. Baverstock M, Woodhall N, Maarman V. P94 Do healthcare professionals have sufficient knowledge of inhaler techniques in order to educate their patients effectively in their use? *Thorax*. 2010;65(Suppl 4):A117. doi:10.1136/thx.2010.150979.45. [https://thorax.bmj.com/content/65/Suppl\\_4/A117.3](https://thorax.bmj.com/content/65/Suppl_4/A117.3)
18. Primary Care Respiratory Society (PCRS). Position statement: Environmental issues. 2023. <https://www.pcrs-uk.org/resource/current/pcrs-position-statement-environmental-issues>
19. Vincken W, Levy ML, Scullion J, Usmani OS, Dekhuijzen PNR, Corrigan CJ. Spacer devices for inhaled therapy: why use them, and how? *ERJ Open Res*. 2018;4(2):00065-02018. doi:10.1183/23120541.00065-2018. <https://pmc.ncbi.nlm.nih.gov/articles/PMC6004521/>
20. Suggett J, Patel J, Nagel M, Carroll W. S64 Impact of choice of salbutamol pMDI and use of spacer on drug delivery and emissions – best for patient and environment. *Thorax*. 2022;77(Suppl 1):A41. doi:10.1136/thorax-2022-BTSabstracts.70. [https://thorax.bmj.com/content/77/Suppl\\_1/A41.1](https://thorax.bmj.com/content/77/Suppl_1/A41.1)
21. Levy ML, Dekhuijzen PNR, Barnes PJ, et al. Inhaler technique: facts and fantasies. A view from the Aerosol Drug Management Improvement Team (ADMIT). *NPJ Prim Care Respir Med*. 2016;26(1):16017. doi:10.1038/npjpcrm.2016.17. <https://pubmed.ncbi.nlm.nih.gov/27098045/>
22. Rickenbach MA, Julious SA. Assessing fullness of asthma patients' aerosol inhalers. *Br J Gen Pract*. 1994;44(384):317-318. Accessed November 6, 2024. <https://pubmed.ncbi.nlm.nih.gov/7619099/>
23. Sander N, Fusco-Walker SJ, Harder JM, Chipps BE. Dose counting and the use of pressurized metered-dose inhalers: Running on empty. *Annals of Allergy, Asthma and Immunology*. 2006;97(1):34-38. doi:10.1016/S1081-1206(10)61366-X. <https://www.sciencedirect.com/science/article/abs/pii/S108112061061366X>
24. Murphy A, Howlett D, Gowson A, Lewis H. Understanding the feasibility and environmental effectiveness of a pilot postal inhaler recovery and recycling scheme. *NPJ Prim Care Respir Med*. 2023;33(1):5. doi:10.1038/S41533-023-00327-W. <https://pubmed.ncbi.nlm.nih.gov/36681666/>

## Other articles which may be of interest

- Chiesi Ltd. Chiesi's carbon minimal inhalers reach innovation milestone as phase III trials now underway. <https://www.pharmiweb.com/press-release/2024-04-05/chiesi-s-carbon-minimal-inhalers-reach-innovation-milestone-as-phase-iii-trials-now-underway-1>
- Development of HFA-152a as a sustainable pMDI propellant - The Aerosol Society. Accessed November 6, 2024. <https://aerosol-soc.com/abstracts/development-of-hfa-152a-as-a-sustainable-pmdi-propellant/>
- Greener inhaler propellant is therapeutically equivalent to traditional alternatives, study results suggest. Pharmaceutical Journal. Published online June 21, 2024. doi:10.1211/PJ.2024.1.321319. <https://pharmaceutical-journal.com/article/news/greener-inhaler-propellant-is-therapeutically-equivalent-to-traditional-alternatives-study-results-suggest>

### **Access the article “Blanket” switching of inhaler types: Why is this a bad idea?’.**

We are grateful to Chiesi Ltd for the provision of a grant to support the activities of the PCRS Greener Respiratory Healthcare campaign. The campaign has been solely organised by PCRS and Chiesi Ltd has had no input in the content.



This resource is part of the PCRS Greener Healthcare Initiative - learn more on the PCRS website: [www.pcrs-uk.org](http://www.pcrs-uk.org)